In our study, fruquintinib treatment led to the upregulation of E-cadherin and the downregulation of N-cadherin, vimentin, and MMP9, suggesting that it inhibits EMT and may reduce CRC cell motility and invasiveness. Here, CDH2 is linked to colorectal carcinoma.